E160 - (CME) Novel Agents for Treating Major Depressive Disorder (MDD)
NEI Podcast
The Role of GABA in Depression
The GABA system may be involved in the pathophysiology of depression. Inflammation kind of rerout signaling in the brain, which is linked to anhedonia and negative moods. There's also evidence that HPA abnormalities are often seen in depressed people. The question now is whether they're downstream effective or not.
In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD.
Learning Objectives: After completing this educational activity, you should be better able to:
- Describe novel mechanisms of action of agents under investigation for the treatment of depression
- Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression
- Integrate newly available options for depression into clinical practice
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.
Credit Types. The following are being offered for this activity:
- Nurse Practitioner: ANCC contact hours
- Pharmacy: ACPE application-based contact hours
- Physician: ACCME AMA PRA Category 1 Credits ™
- Physician Assistant: AAPA Category 1 CME credits
- Psychology: APA CE credits
- Social Work: ASWB-ACE CE credits
- Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented.
Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva
Interviewee Vladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda
Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.
The Planning Committee and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout.
Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc.
Released: September 26, 2022 CME/CE credit expires: September 26, 2025
The AI-powered Podcast Player
